187 related articles for article (PubMed ID: 28923834)
21. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
22. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Holtkamp FA; de Zeeuw D; Thomas MC; Cooper ME; de Graeff PA; Hillege HJ; Parving HH; Brenner BM; Shahinfar S; Lambers Heerspink HJ
Kidney Int; 2011 Aug; 80(3):282-7. PubMed ID: 21451458
[TBL] [Abstract][Full Text] [Related]
23. Kidney disease as CVD risk factor: implications for therapy.
Cardiovasc J S Afr; 2005; 16(2):128-9. PubMed ID: 15915283
[No Abstract] [Full Text] [Related]
24. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
25. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
26. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
[TBL] [Abstract][Full Text] [Related]
27. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
[TBL] [Abstract][Full Text] [Related]
28. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Salcedo-Alejos M; Banda-Espinoza F; Rodríguez-Morán M; Guerrero-Romero F
Nephrol Dial Transplant; 2005 Oct; 20(10):2120-5. PubMed ID: 16091379
[TBL] [Abstract][Full Text] [Related]
29. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R; Judge PK; Staplin N; Herrington WG; Storey BC; Bethel A; Bowman L; Brunskill N; Cockwell P; Hill M; Kalra PA; McMurray JJV; Taal M; Wheeler DC; Landray MJ; Baigent C
Circulation; 2018 Oct; 138(15):1505-1514. PubMed ID: 30002098
[TBL] [Abstract][Full Text] [Related]
30. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
31. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Gialama F; Maniadakis N
Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
[TBL] [Abstract][Full Text] [Related]
33. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Ribeiro AB; Gavras H
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):327-33. PubMed ID: 16767299
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
Kjaergaard KD; Peters CD; Jespersen B; Tietze IN; Madsen JK; Pedersen BB; Novosel MK; Laursen KS; Bibby BM; Strandhave C; Jensen JD
Am J Kidney Dis; 2014 Dec; 64(6):892-901. PubMed ID: 25011693
[TBL] [Abstract][Full Text] [Related]
36. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
37. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
38. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Rossing K; Schjoedt KJ; Jensen BR; Boomsma F; Parving HH
Kidney Int; 2005 Sep; 68(3):1190-8. PubMed ID: 16105050
[TBL] [Abstract][Full Text] [Related]
39. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
